Shopping Cart 0
Cart Subtotal
USD 0

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 11985

Details

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

Summary

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

The report provides comprehensive information on the pipeline development landscape for is Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

Which companies are the most active within the pipeline for neurodegenerative disorders?

Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to Buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

READ MORE

Table Of Content

Scope

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 25

Introduction 27

Neurodegenerative Disorders Report Coverage 27

Alzheimer's Disease Overview 27

Amyotrophic Lateral Sclerosis Overview 27

Huntington Disease Overview 27

Multiple Sclerosis Overview 27

Parkinson's Disease Overview 27

Therapeutics Development 28

Alzheimer's Disease 28

Amyotrophic Lateral Sclerosis 30

Huntington Disease 32

Multiple Sclerosis 34

Parkinson's Disease 36

Therapeutics under Development by Companies 38

Alzheimer's Disease 38

Amyotrophic Lateral Sclerosis 50

Huntington Disease 55

Multiple Sclerosis 58

Parkinson's Disease 68

Therapeutics under Investigation by Universities/Institutes 75

Alzheimer's Disease 75

Amyotrophic Lateral Sclerosis 78

Huntington Disease 79

Multiple Sclerosis 81

Parkinson's Disease 83

Pipeline Products Glance 85

Alzheimer's Disease 85

Amyotrophic Lateral Sclerosis 88

Huntington Disease 91

Multiple Sclerosis 94

Parkinson's Disease 97

Products under Development by Companies 101

Alzheimer's Disease 101

Amyotrophic Lateral Sclerosis 116

Huntington Disease 120

Multiple Sclerosis 123

Parkinson's Disease 134

Products under Investigation by Universities/Institutes 144

Alzheimer's Disease 144

Amyotrophic Lateral Sclerosis 150

Huntington Disease 152

Multiple Sclerosis 153

Parkinson's Disease 155

Companies Involved in Therapeutics Development 158

Alzheimer's Disease 158

Amyotrophic Lateral Sclerosis 273

Huntington Disease 318

Multiple Sclerosis 346

Parkinson's Disease 439

Therapeutics Assessment 531

Alzheimer's Disease 531

Amyotrophic Lateral Sclerosis 585

Huntington Disease 607

Multiple Sclerosis 617

Parkinson's Disease 656

Dormant Projects 684

Alzheimer's Disease 684

Amyotrophic Lateral Sclerosis 698

Huntington Disease 702

Multiple Sclerosis 705

Parkinson's Disease 714

Discontinued Products 723

Alzheimer's Disease 723

Amyotrophic Lateral Sclerosis 726

Huntington Disease 726

Multiple Sclerosis 727

Parkinson's Disease 728

Product Development Milestones 730

Alzheimer's Disease 730

Amyotrophic Lateral Sclerosis 741

Huntington Disease 752

Multiple Sclerosis 761

Parkinson's Disease 782

Appendix 796

Methodology 796

Coverage 796

Secondary Research 796

Primary Research 796

Expert Panel Validation 796

Contact Us 797

Disclaimer 797


List Of Figure

List of Figures

Number of Products under Development for Alzheimer's Disease 28

Number of Products under Development for Alzheimer's Disease-Comparative Analysis 29

Number of Products under Development for Amyotrophic Lateral Sclerosis 30

Number of Products under Development for Amyotrophic Lateral Sclerosis-Comparative Analysis 31

Number of Products under Development for Huntington Disease 32

Number of Products under Development for Huntington Disease-Comparative Analysis 33

Number of Products under Development for Multiple Sclerosis 34

Number of Products under Development for Multiple Sclerosis-Comparative Analysis 35

Number of Products under Development for Parkinson's Disease 36

Number of Products under Development for Parkinson's Disease-Comparative Analysis 37

Number of Products under Development by Companies, Alzheimer's Disease 38

Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis 50

Number of Products under Development by Companies, Huntington Disease 55

Number of Products under Development by Companies, Multiple Sclerosis 58

Number of Products under Development by Companies, Parkinson's Disease 68

Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease 75

Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 78

Number of Products under Investigation by Universities/Institutes, Huntington Disease 79

Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis 81

Number of Products under Investigation by Universities/Institutes, Parkinson's Disease 83

Comparative Analysis by Late Stage Development, Alzheimer's Disease 85

Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86

Comparative Analysis by Early Stage Products, Alzheimer's Disease 87

Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis 88

Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis 89

Comparative Analysis by Early Stage Products, Amyotrophic Lateral Sclerosis 90

Comparative Analysis by Late Stage Development, Huntington Disease 91

Comparative Analysis by Clinical Stage Development, Huntington Disease 92

Comparative Analysis by Early Stage Products, Huntington Disease 93

Comparative Analysis by Late Stage Development, Multiple Sclerosis 94

Comparative Analysis by Clinical Stage Development, Multiple Sclerosis 95

Comparative Analysis by Early Stage Products, Multiple Sclerosis 96

Comparative Analysis by Late Stage Development, Parkinson's Disease 97

Comparative Analysis by Clinical Stage Development, Parkinson's Disease 98

Comparative Analysis by Early Stage Products, Parkinson's Disease 99

Comparative Analysis by Unknown Stage Development, Parkinson's Disease 100

Assessment by Monotherapy Products, Alzheimer's Disease 531

Assessment by Combination Products, Alzheimer's Disease 532

Number of Products by Top 10 Targets, Alzheimer's Disease 533

Number of Products by Stage and Top 10 Targets, Alzheimer's Disease 533

Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease 556

Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease 556

Number of Products by Top 10 Routes of Administration, Alzheimer's Disease 581

Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease 581

Number of Products by Top 10 Molecule Types, Alzheimer's Disease 583

Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease 583

Assessment by Monotherapy Products, Amyotrophic Lateral Sclerosis 585

Assessment by Combination Products, Amyotrophic Lateral Sclerosis 586

Number of Products by Top 10 Targets, Amyotrophic Lateral Sclerosis 587

Number of Products by Stage and Top 10 Targets, Amyotrophic Lateral Sclerosis 587

Number of Products by Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis 595

Number of Products by Stage and Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis 595

Number of Products by Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis 603

Number of Products by Stage and Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis 603

Number of Products by Top 10 Molecule Types, Amyotrophic Lateral Sclerosis 605

Number of Products by Stage and Top 10 Molecule Types, Amyotrophic Lateral Sclerosis 605

Assessment by Monotherapy Products, Huntington Disease 607

Number of Products by Top 10 Targets, Huntington Disease 608

Number of Products by Stage and Top 10 Targets, Huntington Disease 608

Number of Products by Top 10 Mechanism of Actions, Huntington Disease 611

Number of Products by Stage and Top 10 Mechanism of Actions, Huntington Disease 611

Number of Products by Top 10 Routes of Administration, Huntington Disease 614

Number of Products by Stage and Top 10 Routes of Administration, Huntington Disease 614

Number of Products by Top 10 Molecule Types, Huntington Disease 616

Number of Products by Stage and Top 10 Molecule Types, Huntington Disease 616

Assessment by Monotherapy Products, Multiple Sclerosis 617

Number of Products by Top 10 Targets, Multiple Sclerosis 619

Number of Products by Stage and Top 10 Targets, Multiple Sclerosis 619

Number of Products by Top 10 Mechanism of Actions, Multiple Sclerosis 634

Number of Products by Stage and Top 10 Mechanism of Actions, Multiple Sclerosis 634

Number of Products by Top 10 Routes of Administration, Multiple Sclerosis 652

Number of Products by Stage and Top 10 Routes of Administration, Multiple Sclerosis 652

Number of Products by Top 10 Molecule Types, Multiple Sclerosis 654

Number of Products by Stage and Top 10 Molecule Types, Multiple Sclerosis 654

Assessment by Monotherapy Products, Parkinson's Disease 656

Assessment by Combination Products, Parkinson's Disease 657

Number of Products by Top 10 Targets, Parkinson's Disease 658

Number of Products by Stage and Top 10 Targets, Parkinson's Disease 658

Number of Products by Top 10 Mechanism of Actions, Parkinson's Disease 668

Number of Products by Stage and Top 10 Mechanism of Actions, Parkinson's Disease 668

Number of Products by Top 10 Routes of Administration, Parkinson's Disease 680

Number of Products by Stage and Top 10 Routes of Administration, Parkinson's Disease 680

Number of Products by Top 10 Molecule Types, Parkinson's Disease 682

Number of Products by Stage and Top 10 Molecule Types, Parkinson's Disease 682


List Of Table

List of Tables

Number of Products under Development for Alzheimer's Disease 28

Number of Products under Development for Alzheimer's Disease-Comparative Analysis 29

Number of Products under Development for Amyotrophic Lateral Sclerosis 30

Number of Products under Development for Amyotrophic Lateral Sclerosis-Comparative Analysis 31

Number of Products under Development for Huntington Disease 32

Number of Products under Development for Huntington Disease-Comparative Analysis 33

Number of Products under Development for Multiple Sclerosis 34

Number of Products under Development for Multiple Sclerosis-Comparative Analysis 35

Number of Products under Development for Parkinson's Disease 36

Number of Products under Development for Parkinson's Disease-Comparative Analysis 37

Number of Products under Development by Companies, Alzheimer's Disease 39

Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis 51

Number of Products under Development by Companies, Huntington Disease 55

Number of Products under Development by Companies, Multiple Sclerosis 59

Number of Products under Development by Companies, Parkinson's Disease 68

Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease 75

Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 78

Number of Products under Investigation by Universities/Institutes, Huntington Disease 80

Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis 81

Number of Products under Investigation by Universities/Institutes, Parkinson's Disease 83

Comparative Analysis by Late Stage Development, Alzheimer's Disease 85

Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86

Comparative Analysis by Early Stage Development, Alzheimer's Disease 87

Comparative Analysis by Unknown Stage Development, Alzheimer's Disease 88

Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis 88

Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis 89

Comparative Analysis by Early Stage Development, Amyotrophic Lateral Sclerosis 90

Comparative Analysis by Unknown Stage Development, Amyotrophic Lateral Sclerosis 91

Comparative Analysis by Late Stage Development, Huntington Disease 91

Comparative Analysis by Clinical Stage Development, Huntington Disease 92

Comparative Analysis by Early Stage Development, Huntington Disease 93

Comparative Analysis by Late Stage Development, Multiple Sclerosis 94

Comparative Analysis by Clinical Stage Development, Multiple Sclerosis 95

Comparative Analysis by Early Stage Development, Multiple Sclerosis 96

Comparative Analysis by Unknown Stage Development, Multiple Sclerosis 96

Comparative Analysis by Late Stage Development, Parkinson's Disease 97

Comparative Analysis by Clinical Stage Development, Parkinson's Disease 98

Comparative Analysis by Early Stage Development, Parkinson's Disease 99

Comparative Analysis by Unknown Stage Development, Parkinson's Disease 100

Products under Development by Companies, Alzheimer's Disease 101

Products under Development by Companies, Amyotrophic Lateral Sclerosis 116

Products under Development by Companies, Huntington Disease 120

Products under Development by Companies, Multiple Sclerosis 123

Products under Development by Companies, Parkinson's Disease 134

Products under Investigation by Universities/Institutes, Alzheimer's Disease 144

Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 150

Products under Investigation by Universities/Institutes, Huntington Disease 152

Products under Investigation by Universities/Institutes, Multiple Sclerosis 153

Products under Investigation by Universities/Institutes, Parkinson's Disease 155

Alzheimer's Disease-Pipeline by AB Science SA, 158

Alzheimer's Disease-Pipeline by AbbVie Inc, 159

Alzheimer's Disease-Pipeline by AC Immune SA, 159

Alzheimer's Disease-Pipeline by Accera, Inc., 160

Alzheimer's Disease-Pipeline by Acelot, Inc., 160

Alzheimer's Disease-Pipeline by Actinogen Limited, 161

Alzheimer's Disease-Pipeline by Acumen Pharmaceuticals, Inc., 161

Alzheimer's Disease-Pipeline by Addex Therapeutics Ltd, 162

Alzheimer's Disease-Pipeline by Affibody AB, 162

Alzheimer's Disease-Pipeline by AFFiRiS AG, 163

Alzheimer's Disease-Pipeline by Alector LLC, 163

Alzheimer's Disease-Pipeline by Alkermes Plc, 164

Alzheimer's Disease-Pipeline by Allergan Plc, 164

Alzheimer's Disease-Pipeline by Allinky Biopharma, 165

Alzheimer's Disease-Pipeline by ALSP, Inc., 165

Alzheimer's Disease-Pipeline by Alzhyme Pty Ltd, 166

Alzheimer's Disease-Pipeline by Alzinova AB, 166

Alzheimer's Disease-Pipeline by AlzProtect SAS, 167

Alzheimer's Disease-Pipeline by Amarantus Bioscience Holdings, Inc., 167

Alzheimer's Disease-Pipeline by Amgen Inc., 168

Alzheimer's Disease-Pipeline by Anavex Life Sciences Corp., 169

Alzheimer's Disease-Pipeline by Aphios Corporation, 169

Alzheimer's Disease-Pipeline by Apodemus AB, 170

Alzheimer's Disease-Pipeline by Applied Research using OMIC Sciences, S.L., 170

Alzheimer's Disease-Pipeline by Araclon Biotech, S.L., 171

Alzheimer's Disease-Pipeline by Archer Pharmaceuticals, Inc., 171

Alzheimer's Disease-Pipeline by ArmaGen Inc., 172

Alzheimer's Disease-Pipeline by Artery Therapeutics, Inc., 172

Alzheimer's Disease-Pipeline by AskAt Inc., 172

Alzheimer's Disease-Pipeline by Astellas Pharma Inc., 173

Alzheimer's Disease-Pipeline by AstraZeneca Plc, 174

Alzheimer's Disease-Pipeline by Asubio Pharma Co., Ltd., 175

Alzheimer's Disease-Pipeline by Ausio Pharmaceuticals, LLC, 175

Alzheimer's Disease-Pipeline by Avineuro Pharmaceuticals, Inc., 176

Alzheimer's Disease-Pipeline by Axon Neuroscience SE, 176

Alzheimer's Disease-Pipeline by Axovant Sciences Ltd., 177

Alzheimer's Disease-Pipeline by Axsome Therapeutics, Inc., 177

Alzheimer's Disease-Pipeline by Axxam SpA, 177

Alzheimer's Disease-Pipeline by Beactica AB, 178

Alzheimer's Disease-Pipeline by Berg LLC, 178

Alzheimer's Disease-Pipeline by BioArctic Neuroscience AB, 179

Alzheimer's Disease-Pipeline by Bioasis Technologies Inc., 179

Alzheimer's Disease-Pipeline by Biogen Inc, 180

Alzheimer's Disease-Pipeline by Biomar Microbial Technologies, 180

Alzheimer's Disease-Pipeline by Bionature E.A. Ltd., 181

Alzheimer's Disease-Pipeline by Boehringer Ingelheim GmbH, 181

Alzheimer's Disease-Pipeline by Bristol-Myers Squibb Company, 182

Alzheimer's Disease-Pipeline by Bsim2, 182

Alzheimer's Disease-Pipeline by Cardax Pharmaceuticals, Inc., 183

Alzheimer's Disease-Pipeline by Carna Biosciences, Inc., 183

Alzheimer's Disease-Pipeline by Celon Pharma Sp. z o.o., 184

Alzheimer's Disease-Pipeline by CHA Bio & Diostech Co., Ltd., 184

Alzheimer's Disease-Pipeline by Chase Pharmaceuticals Corporation, 185

Alzheimer's Disease-Pipeline by Clera Inc., 185

Alzheimer's Disease-Pipeline by Cognition Therapeutics, Inc., 186

Alzheimer's Disease-Pipeline by Cognosci, Inc., 186

Alzheimer's Disease-Pipeline by CohBar, Inc., 187

Alzheimer's Disease-Pipeline by Connexios Life Sciences Pvt. Ltd., 187

Alzheimer's Disease-Pipeline by ContraVir Pharmaceuticals, Inc., 188

Alzheimer's Disease-Pipeline by Corium International, Inc., 188

Alzheimer's Disease-Pipeline by Coronis Partners Ltd., 189

Alzheimer's Disease-Pipeline by Cortice Biosciences, Inc., 189

Alzheimer's Disease-Pipeline by Critical Outcome Technologies Inc., 189

Alzheimer's Disease-Pipeline by Crossbeta Biosciences B.V., 190

Alzheimer's Disease-Pipeline by D-Pharm Ltd., 190

Alzheimer's Disease-Pipeline by Daewoong Pharmaceutical Co., Ltd., 191

Alzheimer's Disease-Pipeline by Daiichi Sankyo Company, Limited, 191

Alzheimer's Disease-Pipeline by Daval International Limited, 192

Alzheimer's Disease-Pipeline by DermaXon, LLC, 192

Alzheimer's Disease-Pipeline by Dongkook Pharmaceutical Co., Ltd., 193

Alzheimer's Disease-Pipeline by Eisai Co., Ltd., 193

Alzheimer's Disease-Pipeline by Eli Lilly and Company, 194

Alzheimer's Disease-Pipeline by Emergent BioSolutions Inc., 195

Alzheimer's Disease-Pipeline by EncephRx, Inc., 195

Alzheimer's Disease-Pipeline by Endece, LLC, 196

Alzheimer's Disease-Pipeline by ENKAM Pharmaceuticals A/S, 196

Alzheimer's Disease-Pipeline by Ensemble Therapeutics Corporation, 197

Alzheimer's Disease-Pipeline by Ensol Biosciences Inc., 197

Alzheimer's Disease-Pipeline by Epigen Biosciences, Inc., 198

Alzheimer's Disease-Pipeline by Euroscreen S.A., 198

Alzheimer's Disease-Pipeline by Evotec AG, 199

Alzheimer's Disease-Pipeline by F. Hoffmann-La Roche Ltd., 199

Alzheimer's Disease-Pipeline by FORUM Pharmaceuticals Inc., 200

Alzheimer's Disease-Pipeline by Genentech, Inc., 200

Alzheimer's Disease-Pipeline by Genervon Biopharmaceuticals, LLC, 201

Alzheimer's Disease-Pipeline by GlaxoSmithKline Plc, 201

Alzheimer's Disease-Pipeline by GliaCure Inc., 202

Alzheimer's Disease-Pipeline by Glialogix, Inc., 202

Alzheimer's Disease-Pipeline by Golden Biotechnology Corp., 203

Alzheimer's Disease-Pipeline by Grifols, S.A., 203

Alzheimer's Disease-Pipeline by H. Lundbeck A/S, 204

Alzheimer's Disease-Pipeline by Heptares Therapeutics Limited, 204

Alzheimer's Disease-Pipeline by HitGen LTD, 205

Alzheimer's Disease-Pipeline by Humanetics Corporation, 205

Alzheimer's Disease-Pipeline by Ichor Medical Systems, Inc., 206

Alzheimer's Disease-Pipeline by Icure Pharmaceutical Inc., 206

Alzheimer's Disease-Pipeline by Immungenetics AG, 207

Alzheimer's Disease-Pipeline by Impel NeuroPharma, Inc., 207

Alzheimer's Disease-Pipeline by ImStar Therapeutics Inc., 208

Alzheimer's Disease-Pipeline by Inovio Pharmaceuticals, Inc., 208

Alzheimer's Disease-Pipeline by IntelGenx Corp., 209

Alzheimer's Disease-Pipeline by Intellect Neurosciences, Inc., 209

Alzheimer's Disease-Pipeline by Intra-Cellular Therapies, Inc., 210

Alzheimer's Disease-Pipeline by INVENT Pharmaceuticals, Inc., 210

Alzheimer's Disease-Pipeline by Io Therapeutics, Inc., 211

Alzheimer's Disease-Pipeline by Iproteos S.L., 211

Alzheimer's Disease-Pipeline by Jeil Pharmaceutical Co., Ltd., 212

Alzheimer's Disease-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., 212

Alzheimer's Disease-Pipeline by Johnson & Johnson, 213

Alzheimer's Disease-Pipeline by K-Stemcell Co., Ltd., 213

Alzheimer's Disease-Pipeline by Kadmon Corporation, LLC, 214

Alzheimer's Disease-Pipeline by Kalgene Pharmaceuticals Inc., 214

Alzheimer's Disease-Pipeline by Kareus Therapeutics, SA, 215

Alzheimer's Disease-Pipeline by KineMed, Inc., 215

Alzheimer's Disease-Pipeline by Krenitsky Pharmaceuticals Inc., 216

Alzheimer's Disease-Pipeline by Kyowa Hakko Kirin Co., Ltd., 216

Alzheimer's Disease-Pipeline by Lead Discovery Center GmbH, 217

Alzheimer's Disease-Pipeline by Les Laboratoires Servier SAS, 217

Alzheimer's Disease-Pipeline by Lipopharma Therapeutics SL, 218

Alzheimer's Disease-Pipeline by Living Cell Technologies Limited, 218

Alzheimer's Disease-Pipeline by Lupin Limited, 219

Alzheimer's Disease-Pipeline by M3 Biotechnology, Inc., 219

Alzheimer's Disease-Pipeline by ManRos Therapeutics, 220

Alzheimer's Disease-Pipeline by MedDay SA, 220

Alzheimer's Disease-Pipeline by Medestea Research & Production S.p.A., 221

Alzheimer's Disease-Pipeline by MedImmune, LLC, 221

Alzheimer's Disease-Pipeline by Medisyn Technologies, Inc., 222

Alzheimer's Disease-Pipeline by MEDRx Co., Ltd., 222

Alzheimer's Disease-Pipeline by Merck & Co., Inc., 223

Alzheimer's Disease-Pipeline by Metabolic Solutions Development Company, LLC, 223

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

Summary

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

The report provides comprehensive information on the pipeline development landscape for is Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

Which companies are the most active within the pipeline for neurodegenerative disorders?

Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to Buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

READ MORE

Scope

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 25

Introduction 27

Neurodegenerative Disorders Report Coverage 27

Alzheimer's Disease Overview 27

Amyotrophic Lateral Sclerosis Overview 27

Huntington Disease Overview 27

Multiple Sclerosis Overview 27

Parkinson's Disease Overview 27

Therapeutics Development 28

Alzheimer's Disease 28

Amyotrophic Lateral Sclerosis 30

Huntington Disease 32

Multiple Sclerosis 34

Parkinson's Disease 36

Therapeutics under Development by Companies 38

Alzheimer's Disease 38

Amyotrophic Lateral Sclerosis 50

Huntington Disease 55

Multiple Sclerosis 58

Parkinson's Disease 68

Therapeutics under Investigation by Universities/Institutes 75

Alzheimer's Disease 75

Amyotrophic Lateral Sclerosis 78

Huntington Disease 79

Multiple Sclerosis 81

Parkinson's Disease 83

Pipeline Products Glance 85

Alzheimer's Disease 85

Amyotrophic Lateral Sclerosis 88

Huntington Disease 91

Multiple Sclerosis 94

Parkinson's Disease 97

Products under Development by Companies 101

Alzheimer's Disease 101

Amyotrophic Lateral Sclerosis 116

Huntington Disease 120

Multiple Sclerosis 123

Parkinson's Disease 134

Products under Investigation by Universities/Institutes 144

Alzheimer's Disease 144

Amyotrophic Lateral Sclerosis 150

Huntington Disease 152

Multiple Sclerosis 153

Parkinson's Disease 155

Companies Involved in Therapeutics Development 158

Alzheimer's Disease 158

Amyotrophic Lateral Sclerosis 273

Huntington Disease 318

Multiple Sclerosis 346

Parkinson's Disease 439

Therapeutics Assessment 531

Alzheimer's Disease 531

Amyotrophic Lateral Sclerosis 585

Huntington Disease 607

Multiple Sclerosis 617

Parkinson's Disease 656

Dormant Projects 684

Alzheimer's Disease 684

Amyotrophic Lateral Sclerosis 698

Huntington Disease 702

Multiple Sclerosis 705

Parkinson's Disease 714

Discontinued Products 723

Alzheimer's Disease 723

Amyotrophic Lateral Sclerosis 726

Huntington Disease 726

Multiple Sclerosis 727

Parkinson's Disease 728

Product Development Milestones 730

Alzheimer's Disease 730

Amyotrophic Lateral Sclerosis 741

Huntington Disease 752

Multiple Sclerosis 761

Parkinson's Disease 782

Appendix 796

Methodology 796

Coverage 796

Secondary Research 796

Primary Research 796

Expert Panel Validation 796

Contact Us 797

Disclaimer 797


List Of Figure

List of Figures

Number of Products under Development for Alzheimer's Disease 28

Number of Products under Development for Alzheimer's Disease-Comparative Analysis 29

Number of Products under Development for Amyotrophic Lateral Sclerosis 30

Number of Products under Development for Amyotrophic Lateral Sclerosis-Comparative Analysis 31

Number of Products under Development for Huntington Disease 32

Number of Products under Development for Huntington Disease-Comparative Analysis 33

Number of Products under Development for Multiple Sclerosis 34

Number of Products under Development for Multiple Sclerosis-Comparative Analysis 35

Number of Products under Development for Parkinson's Disease 36

Number of Products under Development for Parkinson's Disease-Comparative Analysis 37

Number of Products under Development by Companies, Alzheimer's Disease 38

Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis 50

Number of Products under Development by Companies, Huntington Disease 55

Number of Products under Development by Companies, Multiple Sclerosis 58

Number of Products under Development by Companies, Parkinson's Disease 68

Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease 75

Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 78

Number of Products under Investigation by Universities/Institutes, Huntington Disease 79

Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis 81

Number of Products under Investigation by Universities/Institutes, Parkinson's Disease 83

Comparative Analysis by Late Stage Development, Alzheimer's Disease 85

Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86

Comparative Analysis by Early Stage Products, Alzheimer's Disease 87

Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis 88

Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis 89

Comparative Analysis by Early Stage Products, Amyotrophic Lateral Sclerosis 90

Comparative Analysis by Late Stage Development, Huntington Disease 91

Comparative Analysis by Clinical Stage Development, Huntington Disease 92

Comparative Analysis by Early Stage Products, Huntington Disease 93

Comparative Analysis by Late Stage Development, Multiple Sclerosis 94

Comparative Analysis by Clinical Stage Development, Multiple Sclerosis 95

Comparative Analysis by Early Stage Products, Multiple Sclerosis 96

Comparative Analysis by Late Stage Development, Parkinson's Disease 97

Comparative Analysis by Clinical Stage Development, Parkinson's Disease 98

Comparative Analysis by Early Stage Products, Parkinson's Disease 99

Comparative Analysis by Unknown Stage Development, Parkinson's Disease 100

Assessment by Monotherapy Products, Alzheimer's Disease 531

Assessment by Combination Products, Alzheimer's Disease 532

Number of Products by Top 10 Targets, Alzheimer's Disease 533

Number of Products by Stage and Top 10 Targets, Alzheimer's Disease 533

Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease 556

Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease 556

Number of Products by Top 10 Routes of Administration, Alzheimer's Disease 581

Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease 581

Number of Products by Top 10 Molecule Types, Alzheimer's Disease 583

Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease 583

Assessment by Monotherapy Products, Amyotrophic Lateral Sclerosis 585

Assessment by Combination Products, Amyotrophic Lateral Sclerosis 586

Number of Products by Top 10 Targets, Amyotrophic Lateral Sclerosis 587

Number of Products by Stage and Top 10 Targets, Amyotrophic Lateral Sclerosis 587

Number of Products by Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis 595

Number of Products by Stage and Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis 595

Number of Products by Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis 603

Number of Products by Stage and Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis 603

Number of Products by Top 10 Molecule Types, Amyotrophic Lateral Sclerosis 605

Number of Products by Stage and Top 10 Molecule Types, Amyotrophic Lateral Sclerosis 605

Assessment by Monotherapy Products, Huntington Disease 607

Number of Products by Top 10 Targets, Huntington Disease 608

Number of Products by Stage and Top 10 Targets, Huntington Disease 608

Number of Products by Top 10 Mechanism of Actions, Huntington Disease 611

Number of Products by Stage and Top 10 Mechanism of Actions, Huntington Disease 611

Number of Products by Top 10 Routes of Administration, Huntington Disease 614

Number of Products by Stage and Top 10 Routes of Administration, Huntington Disease 614

Number of Products by Top 10 Molecule Types, Huntington Disease 616

Number of Products by Stage and Top 10 Molecule Types, Huntington Disease 616

Assessment by Monotherapy Products, Multiple Sclerosis 617

Number of Products by Top 10 Targets, Multiple Sclerosis 619

Number of Products by Stage and Top 10 Targets, Multiple Sclerosis 619

Number of Products by Top 10 Mechanism of Actions, Multiple Sclerosis 634

Number of Products by Stage and Top 10 Mechanism of Actions, Multiple Sclerosis 634

Number of Products by Top 10 Routes of Administration, Multiple Sclerosis 652

Number of Products by Stage and Top 10 Routes of Administration, Multiple Sclerosis 652

Number of Products by Top 10 Molecule Types, Multiple Sclerosis 654

Number of Products by Stage and Top 10 Molecule Types, Multiple Sclerosis 654

Assessment by Monotherapy Products, Parkinson's Disease 656

Assessment by Combination Products, Parkinson's Disease 657

Number of Products by Top 10 Targets, Parkinson's Disease 658

Number of Products by Stage and Top 10 Targets, Parkinson's Disease 658

Number of Products by Top 10 Mechanism of Actions, Parkinson's Disease 668

Number of Products by Stage and Top 10 Mechanism of Actions, Parkinson's Disease 668

Number of Products by Top 10 Routes of Administration, Parkinson's Disease 680

Number of Products by Stage and Top 10 Routes of Administration, Parkinson's Disease 680

Number of Products by Top 10 Molecule Types, Parkinson's Disease 682

Number of Products by Stage and Top 10 Molecule Types, Parkinson's Disease 682


List Of Table

List of Tables

Number of Products under Development for Alzheimer's Disease 28

Number of Products under Development for Alzheimer's Disease-Comparative Analysis 29

Number of Products under Development for Amyotrophic Lateral Sclerosis 30

Number of Products under Development for Amyotrophic Lateral Sclerosis-Comparative Analysis 31

Number of Products under Development for Huntington Disease 32

Number of Products under Development for Huntington Disease-Comparative Analysis 33

Number of Products under Development for Multiple Sclerosis 34

Number of Products under Development for Multiple Sclerosis-Comparative Analysis 35

Number of Products under Development for Parkinson's Disease 36

Number of Products under Development for Parkinson's Disease-Comparative Analysis 37

Number of Products under Development by Companies, Alzheimer's Disease 39

Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis 51

Number of Products under Development by Companies, Huntington Disease 55

Number of Products under Development by Companies, Multiple Sclerosis 59

Number of Products under Development by Companies, Parkinson's Disease 68

Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease 75

Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 78

Number of Products under Investigation by Universities/Institutes, Huntington Disease 80

Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis 81

Number of Products under Investigation by Universities/Institutes, Parkinson's Disease 83

Comparative Analysis by Late Stage Development, Alzheimer's Disease 85

Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86

Comparative Analysis by Early Stage Development, Alzheimer's Disease 87

Comparative Analysis by Unknown Stage Development, Alzheimer's Disease 88

Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis 88

Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis 89

Comparative Analysis by Early Stage Development, Amyotrophic Lateral Sclerosis 90

Comparative Analysis by Unknown Stage Development, Amyotrophic Lateral Sclerosis 91

Comparative Analysis by Late Stage Development, Huntington Disease 91

Comparative Analysis by Clinical Stage Development, Huntington Disease 92

Comparative Analysis by Early Stage Development, Huntington Disease 93

Comparative Analysis by Late Stage Development, Multiple Sclerosis 94

Comparative Analysis by Clinical Stage Development, Multiple Sclerosis 95

Comparative Analysis by Early Stage Development, Multiple Sclerosis 96

Comparative Analysis by Unknown Stage Development, Multiple Sclerosis 96

Comparative Analysis by Late Stage Development, Parkinson's Disease 97

Comparative Analysis by Clinical Stage Development, Parkinson's Disease 98

Comparative Analysis by Early Stage Development, Parkinson's Disease 99

Comparative Analysis by Unknown Stage Development, Parkinson's Disease 100

Products under Development by Companies, Alzheimer's Disease 101

Products under Development by Companies, Amyotrophic Lateral Sclerosis 116

Products under Development by Companies, Huntington Disease 120

Products under Development by Companies, Multiple Sclerosis 123

Products under Development by Companies, Parkinson's Disease 134

Products under Investigation by Universities/Institutes, Alzheimer's Disease 144

Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 150

Products under Investigation by Universities/Institutes, Huntington Disease 152

Products under Investigation by Universities/Institutes, Multiple Sclerosis 153

Products under Investigation by Universities/Institutes, Parkinson's Disease 155

Alzheimer's Disease-Pipeline by AB Science SA, 158

Alzheimer's Disease-Pipeline by AbbVie Inc, 159

Alzheimer's Disease-Pipeline by AC Immune SA, 159

Alzheimer's Disease-Pipeline by Accera, Inc., 160

Alzheimer's Disease-Pipeline by Acelot, Inc., 160

Alzheimer's Disease-Pipeline by Actinogen Limited, 161

Alzheimer's Disease-Pipeline by Acumen Pharmaceuticals, Inc., 161

Alzheimer's Disease-Pipeline by Addex Therapeutics Ltd, 162

Alzheimer's Disease-Pipeline by Affibody AB, 162

Alzheimer's Disease-Pipeline by AFFiRiS AG, 163

Alzheimer's Disease-Pipeline by Alector LLC, 163

Alzheimer's Disease-Pipeline by Alkermes Plc, 164

Alzheimer's Disease-Pipeline by Allergan Plc, 164

Alzheimer's Disease-Pipeline by Allinky Biopharma, 165

Alzheimer's Disease-Pipeline by ALSP, Inc., 165

Alzheimer's Disease-Pipeline by Alzhyme Pty Ltd, 166

Alzheimer's Disease-Pipeline by Alzinova AB, 166

Alzheimer's Disease-Pipeline by AlzProtect SAS, 167

Alzheimer's Disease-Pipeline by Amarantus Bioscience Holdings, Inc., 167

Alzheimer's Disease-Pipeline by Amgen Inc., 168

Alzheimer's Disease-Pipeline by Anavex Life Sciences Corp., 169

Alzheimer's Disease-Pipeline by Aphios Corporation, 169

Alzheimer's Disease-Pipeline by Apodemus AB, 170

Alzheimer's Disease-Pipeline by Applied Research using OMIC Sciences, S.L., 170

Alzheimer's Disease-Pipeline by Araclon Biotech, S.L., 171

Alzheimer's Disease-Pipeline by Archer Pharmaceuticals, Inc., 171

Alzheimer's Disease-Pipeline by ArmaGen Inc., 172

Alzheimer's Disease-Pipeline by Artery Therapeutics, Inc., 172

Alzheimer's Disease-Pipeline by AskAt Inc., 172

Alzheimer's Disease-Pipeline by Astellas Pharma Inc., 173

Alzheimer's Disease-Pipeline by AstraZeneca Plc, 174

Alzheimer's Disease-Pipeline by Asubio Pharma Co., Ltd., 175

Alzheimer's Disease-Pipeline by Ausio Pharmaceuticals, LLC, 175

Alzheimer's Disease-Pipeline by Avineuro Pharmaceuticals, Inc., 176

Alzheimer's Disease-Pipeline by Axon Neuroscience SE, 176

Alzheimer's Disease-Pipeline by Axovant Sciences Ltd., 177

Alzheimer's Disease-Pipeline by Axsome Therapeutics, Inc., 177

Alzheimer's Disease-Pipeline by Axxam SpA, 177

Alzheimer's Disease-Pipeline by Beactica AB, 178

Alzheimer's Disease-Pipeline by Berg LLC, 178

Alzheimer's Disease-Pipeline by BioArctic Neuroscience AB, 179

Alzheimer's Disease-Pipeline by Bioasis Technologies Inc., 179

Alzheimer's Disease-Pipeline by Biogen Inc, 180

Alzheimer's Disease-Pipeline by Biomar Microbial Technologies, 180

Alzheimer's Disease-Pipeline by Bionature E.A. Ltd., 181

Alzheimer's Disease-Pipeline by Boehringer Ingelheim GmbH, 181

Alzheimer's Disease-Pipeline by Bristol-Myers Squibb Company, 182

Alzheimer's Disease-Pipeline by Bsim2, 182

Alzheimer's Disease-Pipeline by Cardax Pharmaceuticals, Inc., 183

Alzheimer's Disease-Pipeline by Carna Biosciences, Inc., 183

Alzheimer's Disease-Pipeline by Celon Pharma Sp. z o.o., 184

Alzheimer's Disease-Pipeline by CHA Bio & Diostech Co., Ltd., 184

Alzheimer's Disease-Pipeline by Chase Pharmaceuticals Corporation, 185

Alzheimer's Disease-Pipeline by Clera Inc., 185

Alzheimer's Disease-Pipeline by Cognition Therapeutics, Inc., 186

Alzheimer's Disease-Pipeline by Cognosci, Inc., 186

Alzheimer's Disease-Pipeline by CohBar, Inc., 187

Alzheimer's Disease-Pipeline by Connexios Life Sciences Pvt. Ltd., 187

Alzheimer's Disease-Pipeline by ContraVir Pharmaceuticals, Inc., 188

Alzheimer's Disease-Pipeline by Corium International, Inc., 188

Alzheimer's Disease-Pipeline by Coronis Partners Ltd., 189

Alzheimer's Disease-Pipeline by Cortice Biosciences, Inc., 189

Alzheimer's Disease-Pipeline by Critical Outcome Technologies Inc., 189

Alzheimer's Disease-Pipeline by Crossbeta Biosciences B.V., 190

Alzheimer's Disease-Pipeline by D-Pharm Ltd., 190

Alzheimer's Disease-Pipeline by Daewoong Pharmaceutical Co., Ltd., 191

Alzheimer's Disease-Pipeline by Daiichi Sankyo Company, Limited, 191

Alzheimer's Disease-Pipeline by Daval International Limited, 192

Alzheimer's Disease-Pipeline by DermaXon, LLC, 192

Alzheimer's Disease-Pipeline by Dongkook Pharmaceutical Co., Ltd., 193

Alzheimer's Disease-Pipeline by Eisai Co., Ltd., 193

Alzheimer's Disease-Pipeline by Eli Lilly and Company, 194

Alzheimer's Disease-Pipeline by Emergent BioSolutions Inc., 195

Alzheimer's Disease-Pipeline by EncephRx, Inc., 195

Alzheimer's Disease-Pipeline by Endece, LLC, 196

Alzheimer's Disease-Pipeline by ENKAM Pharmaceuticals A/S, 196

Alzheimer's Disease-Pipeline by Ensemble Therapeutics Corporation, 197

Alzheimer's Disease-Pipeline by Ensol Biosciences Inc., 197

Alzheimer's Disease-Pipeline by Epigen Biosciences, Inc., 198

Alzheimer's Disease-Pipeline by Euroscreen S.A., 198

Alzheimer's Disease-Pipeline by Evotec AG, 199

Alzheimer's Disease-Pipeline by F. Hoffmann-La Roche Ltd., 199

Alzheimer's Disease-Pipeline by FORUM Pharmaceuticals Inc., 200

Alzheimer's Disease-Pipeline by Genentech, Inc., 200

Alzheimer's Disease-Pipeline by Genervon Biopharmaceuticals, LLC, 201

Alzheimer's Disease-Pipeline by GlaxoSmithKline Plc, 201

Alzheimer's Disease-Pipeline by GliaCure Inc., 202

Alzheimer's Disease-Pipeline by Glialogix, Inc., 202

Alzheimer's Disease-Pipeline by Golden Biotechnology Corp., 203

Alzheimer's Disease-Pipeline by Grifols, S.A., 203

Alzheimer's Disease-Pipeline by H. Lundbeck A/S, 204

Alzheimer's Disease-Pipeline by Heptares Therapeutics Limited, 204

Alzheimer's Disease-Pipeline by HitGen LTD, 205

Alzheimer's Disease-Pipeline by Humanetics Corporation, 205

Alzheimer's Disease-Pipeline by Ichor Medical Systems, Inc., 206

Alzheimer's Disease-Pipeline by Icure Pharmaceutical Inc., 206

Alzheimer's Disease-Pipeline by Immungenetics AG, 207

Alzheimer's Disease-Pipeline by Impel NeuroPharma, Inc., 207

Alzheimer's Disease-Pipeline by ImStar Therapeutics Inc., 208

Alzheimer's Disease-Pipeline by Inovio Pharmaceuticals, Inc., 208

Alzheimer's Disease-Pipeline by IntelGenx Corp., 209

Alzheimer's Disease-Pipeline by Intellect Neurosciences, Inc., 209

Alzheimer's Disease-Pipeline by Intra-Cellular Therapies, Inc., 210

Alzheimer's Disease-Pipeline by INVENT Pharmaceuticals, Inc., 210

Alzheimer's Disease-Pipeline by Io Therapeutics, Inc., 211

Alzheimer's Disease-Pipeline by Iproteos S.L., 211

Alzheimer's Disease-Pipeline by Jeil Pharmaceutical Co., Ltd., 212

Alzheimer's Disease-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., 212

Alzheimer's Disease-Pipeline by Johnson & Johnson, 213

Alzheimer's Disease-Pipeline by K-Stemcell Co., Ltd., 213

Alzheimer's Disease-Pipeline by Kadmon Corporation, LLC, 214

Alzheimer's Disease-Pipeline by Kalgene Pharmaceuticals Inc., 214

Alzheimer's Disease-Pipeline by Kareus Therapeutics, SA, 215

Alzheimer's Disease-Pipeline by KineMed, Inc., 215

Alzheimer's Disease-Pipeline by Krenitsky Pharmaceuticals Inc., 216

Alzheimer's Disease-Pipeline by Kyowa Hakko Kirin Co., Ltd., 216

Alzheimer's Disease-Pipeline by Lead Discovery Center GmbH, 217

Alzheimer's Disease-Pipeline by Les Laboratoires Servier SAS, 217

Alzheimer's Disease-Pipeline by Lipopharma Therapeutics SL, 218

Alzheimer's Disease-Pipeline by Living Cell Technologies Limited, 218

Alzheimer's Disease-Pipeline by Lupin Limited, 219

Alzheimer's Disease-Pipeline by M3 Biotechnology, Inc., 219

Alzheimer's Disease-Pipeline by ManRos Therapeutics, 220

Alzheimer's Disease-Pipeline by MedDay SA, 220

Alzheimer's Disease-Pipeline by Medestea Research & Production S.p.A., 221

Alzheimer's Disease-Pipeline by MedImmune, LLC, 221

Alzheimer's Disease-Pipeline by Medisyn Technologies, Inc., 222

Alzheimer's Disease-Pipeline by MEDRx Co., Ltd., 222

Alzheimer's Disease-Pipeline by Merck & Co., Inc., 223

Alzheimer's Disease-Pipeline by Metabolic Solutions Development Company, LLC, 223

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS